The UK’s GlaxoSmithKline and Germany’s CureVac are to develop a new generation of mRNA Covid-19 vaccines to tackle emerging variants that have shown some resistance to current vaccines.
The two companies plan to work on a joint approach to address “multiple emerging variants” in one jab, they said in a statement on Wednesday. The deal is worth €150m, the companies said.
GSK will also help to make up to 100m doses of CureVac’s vaccine candidate through its manufacturing facilities in Belgium. CureVac’s vaccine is going through the final phases of testing.
The companies are targeting the introduction of the variant-specific vaccine in 2022, subject to regulatory approval.
GSK bought close to 10 per cent of CureVac in July, although the deal did not target its current Covid-19 products.